Abstract:Abstract Preclinical studies from us and others have shown that oral intake of next-generation selenium (Se) forms, especially methylseleninic acid (MSeA) and Se-methylselenocysteine (MSeC) inhibits mouse prostate carcinogenesis. Our recent study has shown that MSeA suppresses pten-deficient mouse high grade prostatic intraepithelial neoplasia progression to adenocarcinoma in association with superactivating p53-p21 mediated cellular senescence. To address the question whether the activation of senescence is induced in prostate carcinogenesis driven by different etiology, we sought to test the in vivo effect of different selenium forms fed to rats undergoing chemically induced, androgen promoted prostate carcinogenesis. Wistar-Unilever (WU) rats (10-12 wks) were sequentially treated with androgen receptor blocker flutamide for 21 days (10 mg/kg/day by gavage), followed by testosterone propionate (TP, 10 mg/kg, s.c) on day 22. Three days after TP, chemical carcinogen methylnitrosourea (MNU, 30 mg/kg/bw) was administered by i.p. injection. One week later, the rats received testosterone-containing silastic implants. Rats were randomized to groups fed the AIN-93M diet or supplemented with 3 ppm of Se as MSeA, MSeC, or selenomethionine (SeMet). Separate groups of rats were fed these diets, but did not receive the carcinogen treatment. After 16 weeks of this dietary treatment, rats were euthanized. Blood, major organs and different prostate lobes were dissected and weighed. The body weight of carcinogen-exposed rats was significantly lower than their non-carcinogen-exposed counterparts. However, total prostate complex weight was higher in carcinogen-treated groups than the non-carcinogen groups, consistent with MNU and extra-testicular androgen promoting prostate epithelial cell proliferation. There were no significant organ-to-body weight ratio differences of various prostate lobes in the different dietary groups, regardless of the carcinogen exposure status. In order to test the involvement of senescence in prostate of rats fed different Se diets, we have undertaken steps to optimize staining method for senescence-associated β-galactosidase (SA-βgal) activity in different lobes of prostate frozen sections. Together, with whole slide imaging using an Aperio Digital Pathology Scanner for quantitation, we are afforded an approach for more objective interrogation of the role of senescence in this carcinogenesis model and chemoprevention by selenium compounds. Citation Format: Kartick C. Pramanik, Michael Schlicht, Maarten Bosland, Chang Jiang, Yibin Deng, Junxuan Lu. Studying senescence in prostate of selenium treated rats undergoing carcinogen-induced, androgen-promoted prostate carcinogenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1264. doi:10.1158/1538-7445.AM2017-1264

Prostate Specific Antigen Expression is Down-Regulated by Selenium Through Disruption of Androgen Receptor Signaling.

Selenium Decreases Prostate Specific Antigen Expression by Inducing Protein Degradation and Suppressing Mrna Abundance

Androgen Receptor Signaling Intensity Is A Key Factor In Determining The Sensitivity Of Prostate Cancer Cells To Selenium Inhibition Of Growth And Cancer-Specific Biomarkers

Monomethylated Selenium Inhibits Growth of LNCaP Human Prostate Cancer Xenograft Accompanied by a Decrease in the Expression of Androgen Receptor and Prostate-Specific Antigen (PSA)

Methyl Selenium Metabolites Decrease Prostate-Specific Antigen Expression by Inducing Protein Degradation and Suppressing Androgen-Stimulated Transcription.

The Suppression of Prostate LNCaP Cancer Cells Growth by Selenium Nanoparticles Through Akt/Mdm2/AR Controlled Apoptosis.

Sodium Selenite Inhibits the Expression of VEGF, TGFβ1 and IL-6 Induced by LPS in Human PC3 Cells Via TLR4-NF-KB Signaling Blockage

Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition

Selenium in Prostate Cancer: Prevention, Progression, and Treatment

Abstract 2910: Selenium Nanoparticles Suppress Prostate LNCaP Cancer Cells Growth Through Induced Endogenous Apoptosis

Augmented Suppression of Androgen Receptor Signaling by A Combination of Alpha-Tocopheryl Succinate and Methylseleninic Acid

Selenium Disrupts Estrogen Signaling by Altering Estrogen Receptor Expression and Ligand Binding in Human Breast Cancer Cells

Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds.

Selenium-responsive proteins in the sera of selenium-enriched yeast-supplemented healthy African American and Caucasian men

Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array.

Delineation Of The Molecular Basis For Selenium-Induced Growth Arrest In Human Prostate Cancer Cells By Oligonucleotide Array

Kruppel-Like Factor 4 is A Novel Mediator of Selenium in Growth Inhibition

Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer.

Dietary Factors and Supplements Influencing Prostate Specific-Antigen (PSA) Concentrations in Men with Prostate Cancer and Increased Cancer Risk: An Evidence Analysis Review Based on Randomized Controlled Trials

Abstract 1264: Studying Senescence in Prostate of Selenium Treated Rats Undergoing Carcinogen-Induced, Androgen-Promoted Prostate Carcinogenesis

Inactivation of AR/TMPRSS2-ERG/Wnt Signaling Networks Attenuates the Aggressive Behavior of Prostate Cancer Cells